ID   MP2K1_HUMAN             Reviewed;         393 AA.
AC   Q02750;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   10-MAY-2017, entry version 192.
DE   RecName: Full=Dual specificity mitogen-activated protein kinase kinase 1;
DE            Short=MAP kinase kinase 1;
DE            Short=MAPKK 1;
DE            Short=MKK1;
DE            EC=2.7.12.2;
DE   AltName: Full=ERK activator kinase 1;
DE   AltName: Full=MAPK/ERK kinase 1;
DE            Short=MEK 1;
GN   Name=MAP2K1; Synonyms=MEK1, PRKMK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), PARTIAL PROTEIN
RP   SEQUENCE, AND TISSUE SPECIFICITY.
RC   TISSUE=T-cell;
RX   PubMed=1281467;
RA   Seger R., Seger D., Lozeman F.J., Ahn N.G., Graves L.M.,
RA   Campbell J.S., Ericsson L., Harrylock M., Jensen A.M., Krebs E.G.;
RT   "Human T-cell mitogen-activated protein kinase kinases are related to
RT   yeast signal transduction kinases.";
RL   J. Biol. Chem. 267:25628-25631(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8388392;
RA   Zheng C.-F., Guan K.-L.;
RT   "Cloning and characterization of two distinct human extracellular
RT   signal-regulated kinase activator kinases, MEK1 and MEK2.";
RL   J. Biol. Chem. 268:11435-11439(1993).
RN   [3]
RP   PROTEIN SEQUENCE OF 35-45; 48-57; 175-183 AND 344-353, INTERACTION
RP   WITH KSR1, SUBCELLULAR LOCATION, AND PHOSPHORYLATION AT SER-218.
RX   PubMed=10409742; DOI=10.1128/MCB.19.8.5523;
RA   Stewart S., Sundaram M., Zhang Y., Lee J., Han M., Guan K.L.;
RT   "Kinase suppressor of Ras forms a multiprotein signaling complex and
RT   modulates MEK localization.";
RL   Mol. Cell. Biol. 19:5523-5534(1999).
RN   [4]
RP   PHOSPHORYLATION AT SER-218 AND SER-222, AND MUTAGENESIS OF LYS-97;
RP   SER-150; SER-212; SER-218 AND SER-222.
RX   PubMed=8131746;
RA   Zheng C.-F., Guan K.-L.;
RT   "Activation of MEK family kinases requires phosphorylation of two
RT   conserved Ser/Thr residues.";
RL   EMBO J. 13:1123-1131(1994).
RN   [5]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR, AND PROTEIN SEQUENCE OF 9-17.
RX   PubMed=9563949; DOI=10.1126/science.280.5364.734;
RA   Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R.,
RA   Copeland T.D., Ahn N.G., Oskarsson M.K., Fukasawa K., Paull K.D.,
RA   Vande Woude G.F.;
RT   "Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal
RT   factor.";
RL   Science 280:734-737(1998).
RN   [6]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR.
RX   PubMed=11104681; DOI=10.1042/bj3520739;
RA   Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.;
RT   "Susceptibility of mitogen-activated protein kinase kinase family
RT   members to proteolysis by anthrax lethal factor.";
RL   Biochem. J. 352:739-745(2000).
RN   [7]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=14737111; DOI=10.1038/sj.onc.1207188;
RA   Liu X., Yan S., Zhou T., Terada Y., Erikson R.L.;
RT   "The MAP kinase pathway is required for entry into mitosis and cell
RT   survival.";
RL   Oncogene 23:763-776(2004).
RN   [8]
RP   PHOSPHORYLATION AT SER-298.
RX   PubMed=16129686; DOI=10.1074/jbc.M502306200;
RA   Beeser A., Jaffer Z.M., Hofmann C., Chernoff J.;
RT   "Role of group A p21-activated kinases in activation of extracellular-
RT   regulated kinase by growth factors.";
RL   J. Biol. Chem. 280:36609-36615(2005).
RN   [9]
RP   INTERACTION WITH YOPJ, AND ACETYLATION.
RX   PubMed=16728640; DOI=10.1126/science.1126867;
RA   Mukherjee S., Keitany G., Li Y., Wang Y., Ball H.L., Goldsmith E.J.,
RA   Orth K.;
RT   "Yersinia YopJ acetylates and inhibits kinase activation by blocking
RT   phosphorylation.";
RL   Science 312:1211-1214(2006).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PPARG.
RX   PubMed=17101779; DOI=10.1128/MCB.00601-06;
RA   Burgermeister E., Chuderland D., Hanoch T., Meyer M., Liscovitch M.,
RA   Seger R.;
RT   "Interaction with MEK causes nuclear export and downregulation of
RT   peroxisome proliferator-activated receptor gamma.";
RL   Mol. Cell. Biol. 27:803-817(2007).
RN   [11]
RP   INTERACTION WITH BIRC6/BRUCE.
RX   PubMed=18329369; DOI=10.1016/j.cell.2008.01.012;
RA   Pohl C., Jentsch S.;
RT   "Final stages of cytokinesis and midbody ring formation are controlled
RT   by BRUCE.";
RL   Cell 132:832-845(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-286, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   INTERACTION WITH SGK1.
RX   PubMed=19447520; DOI=10.1016/j.jhep.2009.02.027;
RA   Won M., Park K.A., Byun H.S., Kim Y.R., Choi B.L., Hong J.H., Park J.,
RA   Seok J.H., Lee Y.H., Cho C.H., Song I.S., Kim Y.K., Shen H.M.,
RA   Hur G.M.;
RT   "Protein kinase SGK1 enhances MEK/ERK complex formation through the
RT   phosphorylation of ERK2: implication for the positive regulatory role
RT   of SGK1 on the ERK function during liver regeneration.";
RL   J. Hepatol. 51:67-76(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   INTERACTION WITH VRK2.
RX   PubMed=20679487; DOI=10.1128/MCB.01581-09;
RA   Fernandez I.F., Blanco S., Lozano J., Lazo P.A.;
RT   "VRK2 inhibits mitogen-activated protein kinase signaling and
RT   inversely correlates with ErbB2 in human breast cancer.";
RL   Mol. Cell. Biol. 30:4687-4697(2010).
RN   [16]
RP   REVIEW ON FUNCTION.
RX   PubMed=9779990; DOI=10.1038/sj.onc.1202251;
RA   Dhanasekaran N., Premkumar Reddy E.;
RT   "Signaling by dual specificity kinases.";
RL   Oncogene 17:1447-1455(1998).
RN   [17]
RP   REVIEW ON ENZYME REGULATION.
RX   PubMed=15520807; DOI=10.1038/nrm1498;
RA   Wellbrock C., Karasarides M., Marais R.;
RT   "The RAF proteins take centre stage.";
RL   Nat. Rev. Mol. Cell Biol. 5:875-885(2004).
RN   [18]
RP   REVIEW ON FUNCTION.
RX   PubMed=19565474; DOI=10.1002/biof.52;
RA   Yao Z., Seger R.;
RT   "The ERK signaling cascade--views from different subcellular
RT   compartments.";
RL   BioFactors 35:407-416(2009).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   REVIEW ON FUNCTION.
RX   PubMed=21779493; DOI=10.1177/1947601911407328;
RA   Wortzel I., Seger R.;
RT   "The ERK cascade: distinct functions within various subcellular
RT   organelles.";
RL   Genes Cancer 2:195-209(2011).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 62-392 IN COMPLEX WITH ATP
RP   AND INHIBITOR.
RX   PubMed=15543157; DOI=10.1038/nsmb859;
RA   Ohren J.F., Chen H., Pavlovsky A., Whitehead C., Zhang E., Kuffa P.,
RA   Yan C., McConnell P., Spessard C., Banotai C., Mueller W.T.,
RA   Delaney A., Omer C., Sebolt-Leopold J., Dudley D.T., Leung I.K.,
RA   Flamme C., Warmus J., Kaufman M., Barrett S., Tecle H., Hasemann C.A.;
RT   "Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe
RT   novel noncompetitive kinase inhibition.";
RL   Nat. Struct. Mol. Biol. 11:1192-1197(2004).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 62-393 IN COMPLEX WITH ATP
RP   AND INHIBITOR.
RX   PubMed=17880056; DOI=10.1021/jm0704548;
RA   Spicer J.A., Rewcastle G.W., Kaufman M.D., Black S.L., Plummer M.S.,
RA   Denny W.A., Quin J. III, Shahripour A.B., Barrett S.D.,
RA   Whitehead C.E., Milbank J.B., Ohren J.F., Gowan R.C., Omer C.,
RA   Camp H.S., Esmaeil N., Moore K., Sebolt-Leopold J.S.,
RA   Pryzbranowski S., Merriman R.L., Ortwine D.F., Warmus J.S.,
RA   Flamme C.M., Pavlovsky A.G., Tecle H.;
RT   "4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive
RT   inhibitors of mitogen-activated protein kinase kinase.";
RL   J. Med. Chem. 50:5090-5102(2007).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.62 ANGSTROMS) OF 62-393 IN COMPLEX WITH ATP
RP   AND INHIBITOR.
RX   PubMed=18951019; DOI=10.1016/j.bmcl.2008.10.015;
RA   Warmus J.S., Flamme C., Zhang L.Y., Barrett S., Bridges A., Chen H.,
RA   Gowan R., Kaufman M., Sebolt-Leopold J., Leopold W., Merriman R.,
RA   Ohren J., Pavlovsky A., Przybranowski S., Tecle H., Valik H.,
RA   Whitehead C., Zhang E.;
RT   "2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-
RT   Alkyl benzohydroxamate esters replacements retain the desired
RT   inhibition and selectivity against MEK (MAP ERK kinase).";
RL   Bioorg. Med. Chem. Lett. 18:6171-6174(2008).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 35-393 IN COMPLEX WITH ADP
RP   AND INHIBITOR.
RX   PubMed=19161339; DOI=10.1021/bi801898e;
RA   Fischmann T.O., Smith C.K., Mayhood T.W., Myers J.E., Reichert P.,
RA   Mannarino A., Carr D., Zhu H., Wong J., Yang R.S., Le H.V.,
RA   Madison V.S.;
RT   "Crystal structures of MEK1 binary and ternary complexes with
RT   nucleotides and inhibitors.";
RL   Biochemistry 48:2661-2674(2009).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 62-382 IN COMPLEX WITH ATP
RP   AND INHIBITOR.
RX   PubMed=19019675; DOI=10.1016/j.bmcl.2008.10.108;
RA   Tecle H., Shao J., Li Y., Kothe M., Kazmirski S., Penzotti J.,
RA   Ding Y.H., Ohren J., Moshinsky D., Coli R., Jhawar N., Bora E.,
RA   Jacques-O'Hagan S., Wu J.;
RT   "Beyond the MEK-pocket: can current MEK kinase inhibitors be utilized
RT   to synthesize novel type III NCKIs? Does the MEK-pocket exist in
RT   kinases other than MEK?";
RL   Bioorg. Med. Chem. Lett. 19:226-229(2009).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 62-393 IN COMPLEX WITH ATP
RP   AND INHIBITOR.
RX   PubMed=19706763; DOI=10.1158/0008-5472.CAN-09-0679;
RA   Iverson C., Larson G., Lai C., Yeh L.T., Dadson C., Weingarten P.,
RA   Appleby T., Vo T., Maderna A., Vernier J.M., Hamatake R., Miner J.N.,
RA   Quart B.;
RT   "RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of
RT   MEK1/2 for the treatment of cancer.";
RL   Cancer Res. 69:6839-6847(2009).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 62-382 IN COMPLEX WITH ADP
RP   AND INHIBITOR.
RX   PubMed=20621728; DOI=10.1016/j.bmcl.2010.05.058;
RA   Wallace M.B., Adams M.E., Kanouni T., Mol C.D., Dougan D.R.,
RA   Feher V.A., O'Connell S.M., Shi L., Halkowycz P., Dong Q.;
RT   "Structure-based design and synthesis of pyrrole derivatives as MEK
RT   inhibitors.";
RL   Bioorg. Med. Chem. Lett. 20:4156-4158(2010).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 62-382 IN COMPLEX WITH ATP
RP   AND INHIBITOR.
RX   PubMed=21310613; DOI=10.1016/j.bmcl.2011.01.071;
RA   Dong Q., Dougan D.R., Gong X., Halkowycz P., Jin B., Kanouni T.,
RA   O'Connell S.M., Scorah N., Shi L., Wallace M.B., Zhou F.;
RT   "Discovery of TAK-733, a potent and selective MEK allosteric site
RT   inhibitor for the treatment of cancer.";
RL   Bioorg. Med. Chem. Lett. 21:1315-1319(2011).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 62-393.
RX   PubMed=21316218; DOI=10.1016/j.bmcl.2011.01.062;
RA   Isshiki Y., Kohchi Y., Iikura H., Matsubara Y., Asoh K., Murata T.,
RA   Kohchi M., Mizuguchi E., Tsujii S., Hattori K., Miura T.,
RA   Yoshimura Y., Aida S., Miwa M., Saitoh R., Murao N., Okabe H.,
RA   Belunis C., Janson C., Lukacs C., Schuck V., Shimma N.;
RT   "Design and synthesis of novel allosteric MEK inhibitor CH4987655 as
RT   an orally available anticancer agent.";
RL   Bioorg. Med. Chem. Lett. 21:1795-1801(2011).
RN   [31]
RP   VARIANTS CFC3 SER-53 AND CYS-130.
RX   PubMed=16439621; DOI=10.1126/science.1124642;
RA   Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A.,
RA   Cruz M.S., McCormick F., Rauen K.A.;
RT   "Germline mutations in genes within the MAPK pathway cause cardio-
RT   facio-cutaneous syndrome.";
RL   Science 311:1287-1290(2006).
RN   [32]
RP   VARIANT CFC3 VAL-128.
RX   PubMed=18042262; DOI=10.1111/j.1399-0004.2007.00931.x;
RA   Schulz A.L., Albrecht B., Arici C., van der Burgt I., Buske A.,
RA   Gillessen-Kaesbach G., Heller R., Horn D., Hubner C.A., Korenke G.C.,
RA   Konig R., Kress W., Kruger G., Meinecke P., Mucke J., Plecko B.,
RA   Rossier E., Schinzel A., Schulze A., Seemanova E., Seidel H.,
RA   Spranger S., Tuysuz B., Uhrig S., Wieczorek D., Kutsche K., Zenker M.;
RT   "Mutation and phenotypic spectrum in patients with cardio-facio-
RT   cutaneous and Costello syndrome.";
RL   Clin. Genet. 73:62-70(2008).
CC   -!- FUNCTION: Dual specificity protein kinase which acts as an
CC       essential component of the MAP kinase signal transduction pathway.
CC       Binding of extracellular ligands such as growth factors, cytokines
CC       and hormones to their cell-surface receptors activates RAS and
CC       this initiates RAF1 activation. RAF1 then further activates the
CC       dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both
CC       MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK
CC       cascade, and catalyze the concomitant phosphorylation of a
CC       threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located
CC       in the extracellular signal-regulated kinases MAPK3/ERK1 and
CC       MAPK1/ERK2, leading to their activation and further transduction
CC       of the signal within the MAPK/ERK cascade. Depending on the
CC       cellular context, this pathway mediates diverse biological
CC       functions such as cell growth, adhesion, survival and
CC       differentiation, predominantly through the regulation of
CC       transcription, metabolism and cytoskeletal rearrangements. One
CC       target of the MAPK/ERK cascade is peroxisome proliferator-
CC       activated receptor gamma (PPARG), a nuclear receptor that promotes
CC       differentiation and apoptosis. MAP2K1/MEK1 has been shown to
CC       export PPARG from the nucleus. The MAPK/ERK cascade is also
CC       involved in the regulation of endosomal dynamics, including
CC       lysosome processing and endosome cycling through the perinuclear
CC       recycling compartment (PNRC), as well as in the fragmentation of
CC       the Golgi apparatus during mitosis. {ECO:0000269|PubMed:14737111,
CC       ECO:0000269|PubMed:17101779}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Ras proteins such as HRAS mediate the
CC       activation of RAF proteins such as RAF1 or BRAF which in turn
CC       activate extracellular signal-regulated kinases (ERK) through MAPK
CC       (mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1
CC       and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-
CC       218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-
CC       back regulation by its substrate kinases, such as MAPK1/ERK2.
CC       These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitating
CC       dephosphorylation of the activating residues Ser-218 and Ser-222.
CC       Inhibited by serine/threonine phosphatase 2A (By similarity). Many
CC       inhibitors have been identified including pyrrole derivatives,
CC       TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-
CC       4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Found in a complex with at least BRAF, HRAS, MAP2K1,
CC       MAPK3/ERK1 and RGS14. Forms a heterodimer with MAP2K2/MEK2. Forms
CC       heterodimers with KSR2 which further dimerize to form tetramers.
CC       Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1 (By
CC       similarity). Interacts with PPARG and with isoform 1 of VRK2
CC       (PubMed:20679487, PubMed:17101779). Interacts with Yersinia yopJ
CC       (PubMed:16728640). Interacts with SGK1 (PubMed:19447520).
CC       Interacts with BIRC6/bruce (PubMed:18329369). Interacts with KSR1
CC       (PubMed:10409742). {ECO:0000250|UniProtKB:P29678,
CC       ECO:0000250|UniProtKB:P31938, ECO:0000250|UniProtKB:Q01986,
CC       ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:16728640,
CC       ECO:0000269|PubMed:17101779, ECO:0000269|PubMed:18329369,
CC       ECO:0000269|PubMed:19447520, ECO:0000269|PubMed:20679487}.
CC   -!- INTERACTION:
CC       Q8N9N5:BANP; NbExp=3; IntAct=EBI-492564, EBI-744695;
CC       Q9NR09:BIRC6; NbExp=2; IntAct=EBI-492564, EBI-1765160;
CC       P15056:BRAF; NbExp=54; IntAct=EBI-492564, EBI-365980;
CC       Q9Y297:BTRC; NbExp=3; IntAct=EBI-492564, EBI-307461;
CC       O15519-1:CFLAR; NbExp=3; IntAct=EBI-492564, EBI-4567563;
CC       P28482:MAPK1; NbExp=2; IntAct=EBI-492564, EBI-959949;
CC       P27361:MAPK3; NbExp=2; IntAct=EBI-492564, EBI-73995;
CC       P04049:RAF1; NbExp=31; IntAct=EBI-492564, EBI-365996;
CC       Q86Y07:VRK2; NbExp=2; IntAct=EBI-492564, EBI-1207615;
CC       Q86Y07-1:VRK2; NbExp=2; IntAct=EBI-492564, EBI-1207633;
CC       P46937:YAP1; NbExp=3; IntAct=EBI-492564, EBI-1044059;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule
CC       organizing center, centrosome {ECO:0000269|PubMed:14737111}.
CC       Cytoplasm, cytoskeleton, microtubule organizing center, spindle
CC       pole body {ECO:0000269|PubMed:14737111}. Cytoplasm
CC       {ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:17101779}.
CC       Nucleus {ECO:0000269|PubMed:17101779}. Membrane
CC       {ECO:0000269|PubMed:10409742}; Peripheral membrane protein
CC       {ECO:0000269|PubMed:10409742}. Note=Localizes at centrosomes
CC       during prometaphase, midzone during anaphase and midbody during
CC       telophase/cytokinesis (PubMed:14737111). Membrane localization is
CC       probably regulated by its interaction with KSR1 (PubMed:10409742).
CC       {ECO:0000269|PubMed:10409742, ECO:0000269|PubMed:14737111}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=MKK1a;
CC         IsoId=Q02750-1; Sequence=Displayed;
CC       Name=2; Synonyms=MKK1b;
CC         IsoId=Q02750-2; Sequence=VSP_040500;
CC   -!- TISSUE SPECIFICITY: Widely expressed, with extremely low levels in
CC       brain. {ECO:0000269|PubMed:1281467}.
CC   -!- DOMAIN: The proline-rich region localized between residues 270 and
CC       307 is important for binding to RAF1 and activation of
CC       MAP2K1/MEK1. {ECO:0000250}.
CC   -!- PTM: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinase
CC       kinases (RAF or MEKK1) positively regulates kinase activity. Also
CC       phosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK.
CC       MAPK1/ERK2 phosphorylation of Thr-292 occurs in response to
CC       cellular adhesion and leads to inhibition of Ser-298
CC       phosphorylation by PAK. {ECO:0000269|PubMed:16129686,
CC       ECO:0000269|PubMed:8131746}.
CC   -!- PTM: Acetylation by Yersinia yopJ prevents phosphorylation and
CC       activation, thus blocking the MAPK signaling pathway.
CC       {ECO:0000269|PubMed:16728640}.
CC   -!- DISEASE: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: A
CC       form of cardiofaciocutaneous syndrome, a multiple congenital
CC       anomaly disorder characterized by a distinctive facial appearance,
CC       heart defects and mental retardation. Heart defects include
CC       pulmonic stenosis, atrial septal defects and hypertrophic
CC       cardiomyopathy. Some affected individuals present with ectodermal
CC       abnormalities such as sparse, friable hair, hyperkeratotic skin
CC       lesions and a generalized ichthyosis-like condition. Typical
CC       facial features are similar to Noonan syndrome. They include high
CC       forehead with bitemporal constriction, hypoplastic supraorbital
CC       ridges, downslanting palpebral fissures, a depressed nasal bridge,
CC       and posteriorly angulated ears with prominent helices. Distinctive
CC       features of CFC3 include macrostomia and horizontal shape of
CC       palpebral fissures. {ECO:0000269|PubMed:16439621,
CC       ECO:0000269|PubMed:18042262}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L05624; AAA36318.1; -; mRNA.
DR   EMBL; L11284; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS10216.1; -. [Q02750-1]
DR   PIR; A45100; A45100.
DR   RefSeq; NP_002746.1; NM_002755.3. [Q02750-1]
DR   RefSeq; XP_016877900.1; XM_017022411.1. [Q02750-2]
DR   UniGene; Hs.145442; -.
DR   UniGene; Hs.677223; -.
DR   PDB; 1S9J; X-ray; 2.40 A; A=62-393.
DR   PDB; 2P55; X-ray; 2.80 A; A=62-393.
DR   PDB; 3DV3; X-ray; 2.30 A; A=62-382.
DR   PDB; 3DY7; X-ray; 2.70 A; A=62-393.
DR   PDB; 3E8N; X-ray; 2.50 A; A=62-393.
DR   PDB; 3EQB; X-ray; 2.62 A; A=62-393.
DR   PDB; 3EQC; X-ray; 1.80 A; A=35-393.
DR   PDB; 3EQD; X-ray; 2.10 A; A=35-393.
DR   PDB; 3EQF; X-ray; 2.70 A; A=35-393.
DR   PDB; 3EQG; X-ray; 2.50 A; A=35-393.
DR   PDB; 3EQH; X-ray; 2.00 A; A=35-393.
DR   PDB; 3EQI; X-ray; 1.90 A; A=35-393.
DR   PDB; 3MBL; X-ray; 2.60 A; A=62-382.
DR   PDB; 3ORN; X-ray; 2.80 A; A=62-393.
DR   PDB; 3OS3; X-ray; 2.80 A; A=62-393.
DR   PDB; 3PP1; X-ray; 2.70 A; A=62-382.
DR   PDB; 3SLS; X-ray; 2.30 A; A/B=45-263, A/B=308-383.
DR   PDB; 3V01; X-ray; 2.70 A; A=62-393.
DR   PDB; 3V04; X-ray; 2.70 A; A=62-393.
DR   PDB; 3VVH; X-ray; 2.00 A; A/B/C=62-393.
DR   PDB; 3W8Q; X-ray; 2.20 A; A=39-382.
DR   PDB; 3WIG; X-ray; 2.70 A; A=62-393.
DR   PDB; 3ZLS; X-ray; 2.50 A; A=37-383.
DR   PDB; 3ZLW; X-ray; 2.12 A; A=37-383.
DR   PDB; 3ZLX; X-ray; 2.20 A; A=37-383.
DR   PDB; 3ZLY; X-ray; 2.11 A; A=37-383.
DR   PDB; 3ZM4; X-ray; 2.37 A; A=37-383.
DR   PDB; 4AN2; X-ray; 2.50 A; A=61-392.
DR   PDB; 4AN3; X-ray; 2.10 A; A=61-392.
DR   PDB; 4AN9; X-ray; 2.80 A; A=61-392.
DR   PDB; 4ANB; X-ray; 2.20 A; A=61-392.
DR   PDB; 4ARK; X-ray; 2.60 A; A=62-393.
DR   PDB; 4LMN; X-ray; 2.80 A; A=62-393.
DR   PDB; 4MNE; X-ray; 2.85 A; A/D/E/H=62-393.
DR   PDB; 4U7Z; X-ray; 2.80 A; A=62-393.
DR   PDB; 4U80; X-ray; 2.80 A; A=62-393.
DR   PDB; 4U81; X-ray; 2.70 A; A=62-393.
DR   PDB; 5BX0; X-ray; 2.93 A; A=37-383.
DR   PDB; 5EYM; X-ray; 2.70 A; A/B=35-393.
DR   PDBsum; 1S9J; -.
DR   PDBsum; 2P55; -.
DR   PDBsum; 3DV3; -.
DR   PDBsum; 3DY7; -.
DR   PDBsum; 3E8N; -.
DR   PDBsum; 3EQB; -.
DR   PDBsum; 3EQC; -.
DR   PDBsum; 3EQD; -.
DR   PDBsum; 3EQF; -.
DR   PDBsum; 3EQG; -.
DR   PDBsum; 3EQH; -.
DR   PDBsum; 3EQI; -.
DR   PDBsum; 3MBL; -.
DR   PDBsum; 3ORN; -.
DR   PDBsum; 3OS3; -.
DR   PDBsum; 3PP1; -.
DR   PDBsum; 3SLS; -.
DR   PDBsum; 3V01; -.
DR   PDBsum; 3V04; -.
DR   PDBsum; 3VVH; -.
DR   PDBsum; 3W8Q; -.
DR   PDBsum; 3WIG; -.
DR   PDBsum; 3ZLS; -.
DR   PDBsum; 3ZLW; -.
DR   PDBsum; 3ZLX; -.
DR   PDBsum; 3ZLY; -.
DR   PDBsum; 3ZM4; -.
DR   PDBsum; 4AN2; -.
DR   PDBsum; 4AN3; -.
DR   PDBsum; 4AN9; -.
DR   PDBsum; 4ANB; -.
DR   PDBsum; 4ARK; -.
DR   PDBsum; 4LMN; -.
DR   PDBsum; 4MNE; -.
DR   PDBsum; 4U7Z; -.
DR   PDBsum; 4U80; -.
DR   PDBsum; 4U81; -.
DR   PDBsum; 5BX0; -.
DR   PDBsum; 5EYM; -.
DR   ProteinModelPortal; Q02750; -.
DR   SMR; Q02750; -.
DR   BioGrid; 111590; 65.
DR   DIP; DIP-201N; -.
DR   IntAct; Q02750; 63.
DR   MINT; MINT-99632; -.
DR   STRING; 9606.ENSP00000302486; -.
DR   BindingDB; Q02750; -.
DR   ChEMBL; CHEMBL3587; -.
DR   DrugBank; DB06616; Bosutinib.
DR   DrugBank; DB05239; Cobimetinib.
DR   DrugBank; DB02152; K-252a.
DR   DrugBank; DB08911; Trametinib.
DR   GuidetoPHARMACOLOGY; 2062; -.
DR   iPTMnet; Q02750; -.
DR   PhosphoSitePlus; Q02750; -.
DR   BioMuta; MAP2K1; -.
DR   DMDM; 400274; -.
DR   EPD; Q02750; -.
DR   MaxQB; Q02750; -.
DR   PaxDb; Q02750; -.
DR   PeptideAtlas; Q02750; -.
DR   PRIDE; Q02750; -.
DR   DNASU; 5604; -.
DR   Ensembl; ENST00000307102; ENSP00000302486; ENSG00000169032. [Q02750-1]
DR   GeneID; 5604; -.
DR   KEGG; hsa:5604; -.
DR   UCSC; uc010bhq.4; human. [Q02750-1]
DR   CTD; 5604; -.
DR   DisGeNET; 5604; -.
DR   GeneCards; MAP2K1; -.
DR   GeneReviews; MAP2K1; -.
DR   HGNC; HGNC:6840; MAP2K1.
DR   HPA; CAB003834; -.
DR   HPA; HPA026430; -.
DR   MalaCards; MAP2K1; -.
DR   MIM; 176872; gene.
DR   MIM; 615279; phenotype.
DR   neXtProt; NX_Q02750; -.
DR   OpenTargets; ENSG00000169032; -.
DR   Orphanet; 1340; Cardiofaciocutaneous syndrome.
DR   PharmGKB; PA30584; -.
DR   eggNOG; KOG0581; Eukaryota.
DR   eggNOG; ENOG410XQ5A; LUCA.
DR   GeneTree; ENSGT00760000119199; -.
DR   HOGENOM; HOG000234206; -.
DR   HOVERGEN; HBG108518; -.
DR   InParanoid; Q02750; -.
DR   KO; K04368; -.
DR   OMA; LMNHEWI; -.
DR   OrthoDB; EOG091G0DEC; -.
DR   PhylomeDB; Q02750; -.
DR   TreeFam; TF105137; -.
DR   BRENDA; 2.7.12.2; 2681.
DR   Reactome; R-HSA-110056; MAPK3 (ERK1) activation.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-5210891; Uptake and function of anthrax toxins.
DR   Reactome; R-HSA-5673000; RAF activation.
DR   Reactome; R-HSA-5674135; MAP2K and MAPK activation.
DR   Reactome; R-HSA-5674499; Negative feedback regulation of MAPK pathway.
DR   Reactome; R-HSA-5684264; MAP3K8 (TPL2)-dependent MAPK1/3 activation.
DR   Reactome; R-HSA-6802946; Signaling by moderate kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802948; Signaling by high-kinase activity BRAF mutants.
DR   Reactome; R-HSA-6802949; Signaling by RAS mutants.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF fusions.
DR   Reactome; R-HSA-6802955; Paradoxical activation of RAF signaling by kinase inactive BRAF.
DR   SignaLink; Q02750; -.
DR   SIGNOR; Q02750; -.
DR   ChiTaRS; MAP2K1; human.
DR   EvolutionaryTrace; Q02750; -.
DR   GeneWiki; MAP2K1; -.
DR   GenomeRNAi; 5604; -.
DR   PMAP-CutDB; Q02750; -.
DR   PRO; PR:Q02750; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000169032; -.
DR   CleanEx; HS_MAP2K1; -.
DR   ExpressionAtlas; Q02750; baseline and differential.
DR   Genevisible; Q02750; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005769; C:early endosome; TAS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:MGI.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; TAS:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; TAS:UniProtKB.
DR   GO; GO:0005770; C:late endosome; TAS:UniProtKB.
DR   GO; GO:0005815; C:microtubule organizing center; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; TAS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; TAS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004708; F:MAP kinase kinase activity; IDA:UniProtKB.
DR   GO; GO:0008022; F:protein C-terminus binding; IDA:MGI.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0047485; F:protein N-terminus binding; IDA:MGI.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; TAS:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004728; F:signal transducer, downstream of receptor, with protein tyrosine phosphatase activity; IEA:Ensembl.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0000187; P:activation of MAPK activity; IDA:AgBase.
DR   GO; GO:0060020; P:Bergmann glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0007050; P:cell cycle arrest; IMP:BHF-UCL.
DR   GO; GO:0048870; P:cell motility; IEA:Ensembl.
DR   GO; GO:0090398; P:cellular senescence; IMP:BHF-UCL.
DR   GO; GO:0021697; P:cerebellar cortex formation; IEA:Ensembl.
DR   GO; GO:0006935; P:chemotaxis; TAS:ProtInc.
DR   GO; GO:0060502; P:epithelial cell proliferation involved in lung morphogenesis; IEA:Ensembl.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0060324; P:face development; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0060711; P:labyrinthine layer development; IEA:Ensembl.
DR   GO; GO:0000165; P:MAPK cascade; TAS:Reactome.
DR   GO; GO:0006928; P:movement of cell or subcellular component; TAS:ProtInc.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IGI:UniProtKB.
DR   GO; GO:0030182; P:neuron differentiation; IEA:Ensembl.
DR   GO; GO:0060674; P:placenta blood vessel development; IEA:Ensembl.
DR   GO; GO:0050772; P:positive regulation of axonogenesis; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:1903800; P:positive regulation of production of miRNAs involved in gene silencing by miRNA; IMP:BHF-UCL.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IMP:BHF-UCL.
DR   GO; GO:0035897; P:proteolysis in other organism; TAS:Reactome.
DR   GO; GO:0048679; P:regulation of axon regeneration; IEA:Ensembl.
DR   GO; GO:2000641; P:regulation of early endosome to late endosome transport; TAS:UniProtKB.
DR   GO; GO:0090170; P:regulation of Golgi inheritance; TAS:UniProtKB.
DR   GO; GO:0032872; P:regulation of stress-activated MAPK cascade; TAS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   GO; GO:0030878; P:thyroid gland development; IEA:Ensembl.
DR   GO; GO:0060440; P:trachea formation; IEA:Ensembl.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cardiomyopathy; Complete proteome; Cytoplasm; Cytoskeleton;
KW   Direct protein sequencing; Disease mutation; Ectodermal dysplasia;
KW   Kinase; Membrane; Mental retardation; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase; Tyrosine-protein kinase.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P29678}.
FT   CHAIN         2    393       Dual specificity mitogen-activated
FT                                protein kinase kinase 1.
FT                                /FTId=PRO_0000086365.
FT   DOMAIN       68    361       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      74     82       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:15543157,
FT                                ECO:0000269|PubMed:17880056,
FT                                ECO:0000269|PubMed:18951019,
FT                                ECO:0000269|PubMed:19019675,
FT                                ECO:0000269|PubMed:19706763,
FT                                ECO:0000269|PubMed:21310613}.
FT   NP_BIND     143    146       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:15543157,
FT                                ECO:0000269|PubMed:17880056,
FT                                ECO:0000269|PubMed:18951019,
FT                                ECO:0000269|PubMed:19019675,
FT                                ECO:0000269|PubMed:19706763,
FT                                ECO:0000269|PubMed:21310613}.
FT   NP_BIND     150    153       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:15543157,
FT                                ECO:0000269|PubMed:17880056,
FT                                ECO:0000269|PubMed:18951019,
FT                                ECO:0000269|PubMed:19019675,
FT                                ECO:0000269|PubMed:19706763,
FT                                ECO:0000269|PubMed:21310613}.
FT   NP_BIND     192    195       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:15543157,
FT                                ECO:0000269|PubMed:17880056,
FT                                ECO:0000269|PubMed:18951019,
FT                                ECO:0000269|PubMed:19019675,
FT                                ECO:0000269|PubMed:19706763,
FT                                ECO:0000269|PubMed:21310613}.
FT   REGION       77     78       Inhibitor binding.
FT   REGION      144    146       Inhibitor binding.
FT   REGION      208    212       Inhibitor binding.
FT   REGION      270    307       RAF1-binding. {ECO:0000250}.
FT   COMPBIAS    262    307       Pro-rich.
FT   ACT_SITE    190    190       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      77     77       Inhibitor; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:15543157,
FT                                ECO:0000269|PubMed:17880056,
FT                                ECO:0000269|PubMed:18951019,
FT                                ECO:0000269|PubMed:19019675,
FT                                ECO:0000269|PubMed:19161339,
FT                                ECO:0000269|PubMed:19706763,
FT                                ECO:0000269|PubMed:20621728,
FT                                ECO:0000269|PubMed:21310613}.
FT   BINDING      78     78       Inhibitor; via amide nitrogen and
FT                                carbonyl oxygen.
FT                                {ECO:0000269|PubMed:15543157,
FT                                ECO:0000269|PubMed:17880056,
FT                                ECO:0000269|PubMed:18951019,
FT                                ECO:0000269|PubMed:19019675,
FT                                ECO:0000269|PubMed:19161339,
FT                                ECO:0000269|PubMed:19706763,
FT                                ECO:0000269|PubMed:20621728,
FT                                ECO:0000269|PubMed:21310613}.
FT   BINDING      97     97       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:15543157,
FT                                ECO:0000269|PubMed:17880056,
FT                                ECO:0000269|PubMed:18951019,
FT                                ECO:0000269|PubMed:19019675,
FT                                ECO:0000269|PubMed:19706763,
FT                                ECO:0000269|PubMed:21310613}.
FT   BINDING      97     97       Inhibitor. {ECO:0000269|PubMed:15543157,
FT                                ECO:0000269|PubMed:17880056,
FT                                ECO:0000269|PubMed:18951019,
FT                                ECO:0000269|PubMed:19019675,
FT                                ECO:0000269|PubMed:19161339,
FT                                ECO:0000269|PubMed:19706763,
FT                                ECO:0000269|PubMed:20621728,
FT                                ECO:0000269|PubMed:21310613}.
FT   BINDING     190    190       Inhibitor. {ECO:0000269|PubMed:15543157,
FT                                ECO:0000269|PubMed:17880056,
FT                                ECO:0000269|PubMed:18951019,
FT                                ECO:0000269|PubMed:19019675,
FT                                ECO:0000269|PubMed:19161339,
FT                                ECO:0000269|PubMed:19706763,
FT                                ECO:0000269|PubMed:20621728,
FT                                ECO:0000269|PubMed:21310613}.
FT   BINDING     194    194       Inhibitor; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:15543157,
FT                                ECO:0000269|PubMed:17880056,
FT                                ECO:0000269|PubMed:18951019,
FT                                ECO:0000269|PubMed:19019675,
FT                                ECO:0000269|PubMed:19161339,
FT                                ECO:0000269|PubMed:19706763,
FT                                ECO:0000269|PubMed:20621728,
FT                                ECO:0000269|PubMed:21310613}.
FT   BINDING     208    208       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159,
FT                                ECO:0000269|PubMed:15543157,
FT                                ECO:0000269|PubMed:17880056,
FT                                ECO:0000269|PubMed:18951019,
FT                                ECO:0000269|PubMed:19019675,
FT                                ECO:0000269|PubMed:19706763,
FT                                ECO:0000269|PubMed:21310613}.
FT   BINDING     208    208       Inhibitor. {ECO:0000269|PubMed:15543157,
FT                                ECO:0000269|PubMed:17880056,
FT                                ECO:0000269|PubMed:18951019,
FT                                ECO:0000269|PubMed:19019675,
FT                                ECO:0000269|PubMed:19161339,
FT                                ECO:0000269|PubMed:19706763,
FT                                ECO:0000269|PubMed:20621728,
FT                                ECO:0000269|PubMed:21310613}.
FT   BINDING     212    212       Inhibitor; via amide nitrogen.
FT                                {ECO:0000269|PubMed:15543157,
FT                                ECO:0000269|PubMed:17880056,
FT                                ECO:0000269|PubMed:18951019,
FT                                ECO:0000269|PubMed:19019675,
FT                                ECO:0000269|PubMed:19161339,
FT                                ECO:0000269|PubMed:19706763,
FT                                ECO:0000269|PubMed:20621728,
FT                                ECO:0000269|PubMed:21310613}.
FT   SITE          8      9       Cleavage; by anthrax lethal factor.
FT   MOD_RES     218    218       Phosphoserine; by RAF.
FT                                {ECO:0000269|PubMed:10409742,
FT                                ECO:0000269|PubMed:8131746}.
FT   MOD_RES     222    222       Phosphoserine; by RAF.
FT                                {ECO:0000269|PubMed:8131746}.
FT   MOD_RES     286    286       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     292    292       Phosphothreonine; by MAPK1.
FT                                {ECO:0000250}.
FT   MOD_RES     298    298       Phosphoserine; by PAK.
FT                                {ECO:0000269|PubMed:16129686}.
FT   VAR_SEQ     147    172       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:1281467}.
FT                                /FTId=VSP_040500.
FT   VARIANT      53     53       F -> S (in CFC3; dbSNP:rs121908594).
FT                                {ECO:0000269|PubMed:16439621}.
FT                                /FTId=VAR_035093.
FT   VARIANT     128    128       G -> V (in CFC3; dbSNP:rs730880508).
FT                                {ECO:0000269|PubMed:18042262}.
FT                                /FTId=VAR_069780.
FT   VARIANT     130    130       Y -> C (in CFC3; dbSNP:rs121908595).
FT                                {ECO:0000269|PubMed:16439621}.
FT                                /FTId=VAR_035094.
FT   MUTAGEN      97     97       K->R: Inactivation.
FT                                {ECO:0000269|PubMed:8131746}.
FT   MUTAGEN     150    150       S->A: No loss of activity.
FT                                {ECO:0000269|PubMed:8131746}.
FT   MUTAGEN     212    212       S->A: No loss of activity.
FT                                {ECO:0000269|PubMed:8131746}.
FT   MUTAGEN     218    218       S->A: Inactivation.
FT                                {ECO:0000269|PubMed:8131746}.
FT   MUTAGEN     222    222       S->A: Inactivation.
FT                                {ECO:0000269|PubMed:8131746}.
FT   CONFLICT     52     52       A -> R (in Ref. 3; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    180    180       Missing (in Ref. 3; AA sequence).
FT                                {ECO:0000305}.
FT   HELIX        44     58       {ECO:0000244|PDB:3EQC}.
FT   HELIX        65     67       {ECO:0000244|PDB:3EQC}.
FT   STRAND       68     76       {ECO:0000244|PDB:3EQC}.
FT   STRAND       81     87       {ECO:0000244|PDB:3EQC}.
FT   TURN         88     90       {ECO:0000244|PDB:3EQC}.
FT   STRAND       93    100       {ECO:0000244|PDB:3EQC}.
FT   HELIX       105    115       {ECO:0000244|PDB:3EQC}.
FT   HELIX       116    120       {ECO:0000244|PDB:3EQC}.
FT   STRAND      129    135       {ECO:0000244|PDB:3EQC}.
FT   STRAND      138    143       {ECO:0000244|PDB:3EQC}.
FT   HELIX       151    158       {ECO:0000244|PDB:3EQC}.
FT   HELIX       163    184       {ECO:0000244|PDB:3EQC}.
FT   HELIX       193    195       {ECO:0000244|PDB:3EQC}.
FT   STRAND      196    198       {ECO:0000244|PDB:3EQC}.
FT   TURN        200    202       {ECO:0000244|PDB:3DY7}.
FT   STRAND      204    206       {ECO:0000244|PDB:3EQC}.
FT   HELIX       213    218       {ECO:0000244|PDB:3EQC}.
FT   HELIX       221    223       {ECO:0000244|PDB:3VVH}.
FT   HELIX       227    229       {ECO:0000244|PDB:4AN3}.
FT   HELIX       232    235       {ECO:0000244|PDB:3EQC}.
FT   HELIX       242    258       {ECO:0000244|PDB:3EQC}.
FT   HELIX       268    275       {ECO:0000244|PDB:3EQC}.
FT   HELIX       310    319       {ECO:0000244|PDB:3EQC}.
FT   TURN        327    329       {ECO:0000244|PDB:3EQC}.
FT   HELIX       332    342       {ECO:0000244|PDB:3EQC}.
FT   TURN        346    348       {ECO:0000244|PDB:3EQC}.
FT   HELIX       352    356       {ECO:0000244|PDB:3EQC}.
FT   HELIX       359    366       {ECO:0000244|PDB:3EQC}.
FT   HELIX       371    379       {ECO:0000244|PDB:3EQC}.
SQ   SEQUENCE   393 AA;  43439 MW;  0344118FFC842D51 CRC64;
     MPKKKPTPIQ LNPAPDGSAV NGTSSAETNL EALQKKLEEL ELDEQQRKRL EAFLTQKQKV
     GELKDDDFEK ISELGAGNGG VVFKVSHKPS GLVMARKLIH LEIKPAIRNQ IIRELQVLHE
     CNSPYIVGFY GAFYSDGEIS ICMEHMDGGS LDQVLKKAGR IPEQILGKVS IAVIKGLTYL
     REKHKIMHRD VKPSNILVNS RGEIKLCDFG VSGQLIDSMA NSFVGTRSYM SPERLQGTHY
     SVQSDIWSMG LSLVEMAVGR YPIPPPDAKE LELMFGCQVE GDAAETPPRP RTPGRPLSSY
     GMDSRPPMAI FELLDYIVNE PPPKLPSGVF SLEFQDFVNK CLIKNPAERA DLKQLMVHAF
     IKRSDAEEVD FAGWLCSTIG LNQPSTPTHA AGV
//
